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SECOND TRANSPLANT FOR ACUTE MYELOGENOUS LEUKEMIA RELAPS-
ING AFTER FIRST TRANSPLANT
Kim, H.-J., Min, W.-S., Eom, K.-S., Cho, B.-S., Lee, S., Min, C.-K.,
Cho, S.-G., Kim, D.-W., Lee, J.-W., Kim, C.-C. Catholic HSCT Cen-
ter, St. Mary’s Hospital, Seoul, Republic of Korea.
Second hematopoietic stem cell transplantation (HSCT) may be
an effective salvage therapy in some patients with acute myeloge-
nous leukemia (AML) who relapse after an initial transplant. To in-
vestigate the availability of second HSCT, we reviewed our medical
records of 10 recipients of second allogeneic transplants for leuke-
mia recurring after initial autologous or allogeneic transplantation.
Since year 2002, ten relapsed patients after first HSCT who re-
ceived second HSCT from the available HLA-matched (N 5 7)
or –mismatched (N 5 3) sibling or unrelated donors were retro-
spectively reviewed. The median patient age was 35 (range,
1851) and there were 6 males and 4 females. The median fol-
low-up duration after second transplant was 14 months (range, 4–
59). The majority of patients had intermediate or unfavourable
cytogenetic features. Seven patients were relapsed after autologous
HSCT, as a first transplant. Others received from HLA-matched
sibling donors. The main conditioning regimen for second trans-
plant consisted in cyclophosphamide plus busulfan. For graft-ver-
sus-host-disease (GVHD) prophylaxis, we used combinations of
cyclosporine A or tacrolimus in addition to short-term methotrex-
ate. In all, 6 patients received peripheral blood stem cells. All trans-
planted patients were successfully engrafted. The overall incidence
of acute and chronic GvHD was 60% and 43%, respectively. Two
(20%) patients were relapsed so far. The estimated probability of
disease-free survival rate at 4-year was 50%. The overall 5-year sur-
vival rate was 55%. When we considered the incidence of non-re-
lapse transplant-related mortality (TRM), two recipients (20%)
died due to one from severe acute GvHD and the other from fatal
infectious cause. These results demonstrate that second HSCT
for relapsed AML patients performed with appropriate clinical
schedule is feasible, and is associated with a favourable outcome.Characteristics of patients
StemDiagnosis Age/Sex Cytogenetics1st
transplant2nd
transplantcell
source Conditioning StatusAML, M1 33/F 46 XX Sib allo Sib allo PBSC Busulfex/
CyAlive,
50 mAML, M1 36/M t(8;21),21q,14 Auto Unrelated PBSC Busulfex/Cy/
ATGDied,
4 mAML, M2 35/M inv(16) Auto Sib allo PBSC Busulfex/
CyAlive,
11 mAML, M4 46/M 46 XY Sib allo Sib allo PBSC Busulfex/
CyAlive,
53 mAML, M2 49/F 45 X,-9 Auto Unrelated BM Busulfex/Cy/
ATGAlive,
19 mAML, M2 44/F t(1;1) Auto Unrelated BM Busulfex/Cy Alive,
59 mAML, M2 35/M del(16) Auto Unrelated BM Busulfex/Cy/
ATGDied,
12 mAML, M1 21/F inv(16) Auto Sib allo BM Busulfex/Cy Died,
6 mAML, M5 34/M 47 XX,121,
add(3),
add(15),
t(4;18)Sib allo Sib allo PBSC Busulfex/
Fludarabine/
Ara-CAlive,
6 mAML, M1 18/F 47 XX,121 Auto Sib allo PBSC Busulfex/Cy Died,
24 mIDA/BHAC, idarubicin/N4-behenoyl-1-b-Darabinofuranosylcy-
tosine; FLANG, fludarabine, Ara-C, mitoxantrone, and G-
CSF combination chemotherapy in a sequence manner; Topo,
topotecan; M, mitoxantrone; Vp, etoposide; Cy, cyclophospha-
mide; ATG, anti-thymocyte globulin; TRM, transplant-related
mortality; CR2, second complete remission; CTx, chemother-
apy; F/U, follow-up.326
ONCE DAILY BUSULFAN AND FLUDARABINE IS WELL TOLERATED AND
EFFECTIVE IN OLDER HEAVILY TREATED PATIENTS PRIOR TO UNRE-
LATED DONOR ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANS-
PLANT
Potter, G.W., Bachier, C., Smith, B., Houghman, M., LeMaistre, C.F.,
Shaughnessy, P.J. Texas Transplant Institute, San Antonio, TX.
We report the results of a prospective phase II study using a re-
duced intensity (RI) regimen and unrelated donor hematopoietic
stem cell transplant (HCT) consisting of intravenous busulfan
(Bu) 3.2 mg/kg daily for 2 doses, fludarabine 30 mg/m2 daily
for 5 doses, and ATG 15 mg/kg daily for 4 doses. GVHD pro-
phylaxis was tacrolimus and methotrexate 15 mg/m2 on day 1,
and 10 mg/m2 on days 3 and 6. Twenty-one patients (median
age 60, range 39–67) were treated; 19 were HLA matched with
unrelated donors at A, B, C, DR, and DQ, and 2 pts had unre-
lated donors mismatched at one HLA class I allele, and 9 pts had
one or more autologous HCTs prior to beginning the study. Fol-
low up data is available on 20 pts. Grade II or higher regimen
related toxicity (RRT) was reported in seventeen (85%) pts; gas-
trointestinal (n 5 14), mucositis (n 5 7), hepatic function (n 5
4), fever and infection (n 5 3), pulmonary function (n 5 2),
and renal function (n 5 1). Veno-occlusive disease did not man-
ifest in any pts. Six pts did not receive the full dosage of ATG
because of ATG toxicities, including fever and chills, hypoten-
sion, capillary leak syndrome, and elevated bilirubin levels. The
median day of engraftment was 15 days and 19 (95%) of twenty
pts achieved 100% donor chimerism by day 80. Three pts subse-
quently lost donor chimerism and one never achieved higher than
90% donor chimerism; all 4 pts relapsed. Thirteen pts (65%) de-
veloped grade II or higher overall acute GHVD and chronic
GVHD developed in five pts. Treatment related mortality
(TRM) was 15% (95% confidence interval [CI], 5%-40%) at 3
months, and 35% (95% CI, 17%-63%) at 12 months. The
most common cause of TRM was GVHD and infection. Actuar-
ial overall survival at 3 years was 52% (95% CI, 27%-71%). All
six pts who received reduced ATG dosages developed acute
GVHD and one had relapse of disease, while of the remaining
fourteen pts who received full ATG dosages 7 developed acute
GVHD and 5 had relapse of disease. In conclusion, once daily
Bu and fludarabine and unrelated donor HCT demonstrated
good long term survival and disease control, however, TRM still
exists with this regimen in this heavily treated, older pt popula-
tion. Future use of a co-morbidity scoring tool may help select
pts more suitable for this regimen. ATG significantly contributed
to RRT, while GVHD and its treatment and complications pri-
marily resulted in the TRM. Removing ATG and using other
measures for GVHD prophylaxis and treatment may improve
this RI regimen.327
SAFETY AND TOXICITY OF REDUCED INTENSITY ALLOGENEIC TRANS-
PLANTATIONWITH FLUDARABINE/MELPHALAN IN PATIENTSWITH AD-
VANCED HAEMATOLOGICAL DISEASES. A SINGLE CENTRE EXPERIENCE
Khoo, L., Johnston, A.-M., Larsen, S., Joshua, D., Gibson, J. Royal
Prince Alfred Hospital, Sydney, New South Wales, Australia.
Aim: The safety and toxicity outcomes in a group of patients
with advanced haematological diseases undergoing reduced inten-
sity allogeneic stem cell transplantation using Fludarabine (30
mg/m2) and Melphalan (140 mg/m2) conditioning was examined.
The majority (62%) of these heavily pre-treated patients had
failed previous transplantation (22 autologous, and 1 allogeneic).
Method: Thirty-seven patients underwent Sibling (Full Match) -
19; Mismatch Sibling/Other Family – 4, MatchedUnrelated Donor
– 13 or Umbilical Cord Blood – 1 transplantation. The median pa-
tient age was 50 years (range, 29 – 64 years). Disease at time of trans-
plant was: 6 primary acute leukaemia, 3 secondary acute leukaemia,
3 secondaryMDS, 1 primaryMDS, 11 multiple myeloma, 12 NHL
and 1 myelofibrosis. Results: The median follow-up period was 21
months (range, 0.2 – 84 months. Median survival was 9 months
Poster Session II 121(range 0.2 – 68 months) with 32% (12 patients) remaining alive at
time of analysis. Sustained donor engraftment (neutrophils) oc-
curred in 33 (89%) patients. The median time to neutrophil en-
graftment was 14 days (range 9–27); and for platelet engraftment
19 days (range 13–67). The median length of stay in hospital was
28 days (range 15–71). Twenty eight out of 37 patients (76%)
were discharged from hospital post transplant. Nine patients
(24%) required an Intensive Care admission. Seventeen out of
the 37 patients (46%) had severe mucositis requiring opiates,
with 6 requiring total parental nutrition. Graft vs Host Disease
(GVHD) occurred in 24 individuals; 42% had acute GVHD
(50% had .5 Grade 3 severity) and 55% had chronic GVHD
(44% moderate to severe). The day 100 transplant-related mor-
tality (TRM) was 32%, with the overall (all cause) mortality at
1 year of 51%. GVHD accounted for 6 (24%) deaths, primary
disease 7 (28%) and sepsis 12 (48%). Conclusion:The combina-
tion of Fludarabine/Melphalan as a reduced intensity conditioning
regime in this group of patients with advanced haematological ma-
lignancies can lead to prolonged disease control in up to one third of
patients. However, it is not without its short term and long term
toxicity, and is associated with a high day 100 transplant related
mortality.328
ALLOGENEIC TRANSPLANTATION IN RAPID SUCCESSION FROM TWO
DONORS: IMMUNOLOGIC LESSON FOR STEM CELL ENGRAFTMENT
Zuckerman, T., Haddad, N., Katz, T., Gidoni, O., Faibish, T.,
Rowe, J.M. Rambam Medical Center, Haifa, Israel.
A 40-year old female was diagnosed with stage IIHodgkin disease
in 1998. She was treated with standard therapy, relapsed and under-
went autologous stem cell transplantation (SCT). Two years later
she developed primary CNS B cell diffuse large cell lymphoma,
was treated, relapsed systemically and underwent a second autolo-
gus SCT. Two years later she relapsed again and received various
therapies with partial response. In February 2006 she underwent
matched unrelated donor (MUD) SCT with reduced intensity pro-
tocol containing fludarabine 200mg/m2 andmelphalan 140mg/m2.
GVHD prophylaxis consisted of cyclosporine and a short course of
methotrexate. Donor (female) peripheral blood cells (7.7  106
CD34/kg) were collected in advance and cryopreserved. The cells
were transferred to a smaller freezing tank 24 hours before the
transplant. At the initiation of the transplant procedure the cells
were found to be completely thawed due to leaking tank. The cells
were infused and an aliquot was shown to have a viability of only
20%. The donor registry was contacted but the donor refused a fur-
ther donation at that time.
Hence, a second fully matched male donor was immediately lo-
cated and a BM (1.74  106 CD34 cells/kg) was given, remarkably,
5 days following the first stem cell infusion. No additional chemo-
therapy or immunosuppression was given. Fourteen days following
the 2nd stem cell transplantation the patient developed diffuse ery-
thematous rash, fever and watery diarrhea. Chimerism analysis
(PCR for STR) revealed presence of both donors and no evidence
of patient cells in peripheral blood (Table 1). I.V. solumedrolDays from
1st transplant
Days from
2nd transplant
Stem cell
source
Chimera
1st donor
%
Chimera
2nd donor
%
Fish Y
chromosome
%
18 13 PB2 56 44 ND1
27 22 BM3 42 58 46
33 27 BM 95 5 9
41 35 BM 100 0 1
1Not done.
2Peripheral blood.
3Bone marrow.(2 mg/kg) was started to treat a possible acute GVHD. Repeat anal-
ysis is described in [Table 1]. Unfortunately the patient remained
neutropenic with no evidence for neutrophil and megakaryocyte
precursors in BM.On day 42 from 1st transplant the patient received
CD34 positive stem cells boost (4.4  106cells/kg) from the same
first female donor, engrafted promptly after 7 days and became
transfusion independent. GVHD was not aggravated following
stem cell boost. The patient gradually stopped steroids and cyclo-
sporine and remains alive and well after all immunosuppressive
therapy.
In conclusion, it appears that: (a) Low number of viable and
thawed stem cells can survive and lead to engraftment. (b) Double
allogeneic transplant ultimately leads to selection of a single donor
as described for double cord-blood transplants.329
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SE-
VERE APLASTIC ANEMIA (SAA) USING A NON-MYELOABLATIVE CONDI-
TIONING REGIMEN (NMCR)
Rosenthal, J., Pawlowska, A., Bolotin, E., Falk, P., Oliver, C.,
Forman, S. City of Hope National Medical Center, Duarte, CA.
Allogeneic bone marrow transplantation (ALLOBMT) is a cura-
tive treatment for patients (pts) with acquired SAA. Current prepar-
ative therapies are associated with early and late sequelae such as
organ injury, and secondary malignancies. We report the use of
NMCR in patients with SAA.
Patients andMethods: Four pts, ages 6–12 years, with SAA, had
ALLO BMT from an HLA-identical sibling (SIB) (n 5 2) or
a matched unrelated donor (MUD) (n 5 2). The reasons to offer
NMCR were: delay in results of chromosome fragility studies, ab-
normal pulmonary function, history of recent life threatening infec-
tion, and failure to respond to immunosuppressive therapy. The
NMCR consisted of fludarabine (FLU) (30 mg/m2  4), low dose
cyclophosphamide (LDC) (5 mg/kg  4) and rabbit antithymocyte
globulin (rATG) (1.5 mg/kg  4) in patients with SIB donor and
FLU, LDC, at 15 mg/kg  4, rATG and a single fraction of total
body irradiation at 200 cGy in patients with a MUD donor. Re-
sults: The NMCR was well tolerated in all 4 patients. Two pts
who had a SIB BMT had no transplant-related toxicities, including
mucositis or alopecia. Toxicities in the MUD BMT pts included
mild mucositis and partial alpecia in both pts. One pt (Pt#3) had re-
activation od Enterobacter cloacae sepsis with typhlitis and later
CMV viremia. Myeloid and platelet engraftment were uneventful
in 3 pts. The recovery of peripheral blood counts was slow in Pt
#3 following typhlitis and CMV viremia. Myeloid engraftment oc-
curred on day119 (range 15–33 days). Themedian time to a platelet
count.20,000 unsupported by transfusionwas day133, (range 12–
76 days). Periodic engraftmen anlyses using short tandem repeat
(STR) by PCR continue to show full donor chimerism in all 4
pts. Acute GvHD of the skin was recorded only in the 2 pts with
MUDBMT.One patient had limited chronic GvHD (Pt#3). Three
pts. continue to do well with a fully recovered hematopoietic system
at 44, 19 and 5months post transplant, respectively. Pt #3 had a slow
recovery of her peripheral counts but is transfusion independent for
greater than 2 months and doing well 7 months post-transplant.
Conclusion: This data suggests that a non-myeloablative, immu-
nosuppressive regimen is sufficient to provide a stable engraftment
in the patients with SAA. This approach may be associated with de-
creased transplant-related, short- and long-term, toxicities. A larger
study is needed to fully evaluate the outcome and the toxicity asso-
ciated with this conditioning.330
RITUXIMAB IS FEASIBLE TO ADMINISTER TO ALLOGRAFT RECIPIENTS
WITH ADVANCED CD201 MALIGNANCIES AND DOES NOT AFFECT
TIMELY HEMATOPOIETIC ENGRAFTMENT
Kharfan-Dabaja, M.A.1, Tate, C.1,2, Perkins, J.1, Fernandez, H.F.1,
Field, T.1, Ayala, E.1, Perez, L.1, Raychaudhuri, J.1, Alsina, M.1,
Ochoa-Bayona, L.1, Sullivan, D.1, Brand, L.1, Poling, W.1,
